JP2013503175A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503175A5
JP2013503175A5 JP2012526951A JP2012526951A JP2013503175A5 JP 2013503175 A5 JP2013503175 A5 JP 2013503175A5 JP 2012526951 A JP2012526951 A JP 2012526951A JP 2012526951 A JP2012526951 A JP 2012526951A JP 2013503175 A5 JP2013503175 A5 JP 2013503175A5
Authority
JP
Japan
Prior art keywords
subject
expression level
sarcoma
marker
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012526951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503175A (ja
JP6159085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/046711 external-priority patent/WO2011031503A2/en
Publication of JP2013503175A publication Critical patent/JP2013503175A/ja
Publication of JP2013503175A5 publication Critical patent/JP2013503175A5/ja
Application granted granted Critical
Publication of JP6159085B2 publication Critical patent/JP6159085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012526951A 2009-08-25 2010-08-25 エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法 Expired - Fee Related JP6159085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25
US61/236,845 2009-08-25
PCT/US2010/046711 WO2011031503A2 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015255646A Division JP2016136938A (ja) 2009-08-25 2015-12-28 エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法

Publications (3)

Publication Number Publication Date
JP2013503175A JP2013503175A (ja) 2013-01-31
JP2013503175A5 true JP2013503175A5 (https=) 2013-10-17
JP6159085B2 JP6159085B2 (ja) 2017-07-05

Family

ID=43730801

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012526951A Expired - Fee Related JP6159085B2 (ja) 2009-08-25 2010-08-25 エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法
JP2015255646A Ceased JP2016136938A (ja) 2009-08-25 2015-12-28 エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015255646A Ceased JP2016136938A (ja) 2009-08-25 2015-12-28 エピメタボリックシフター（コエンザイムｑ１０）を使用する肉腫の処置方法

Country Status (15)

Country Link
US (2) US20110064747A1 (https=)
EP (1) EP2470169A4 (https=)
JP (2) JP6159085B2 (https=)
KR (1) KR101572463B1 (https=)
CN (2) CN108245497A (https=)
AU (2) AU2010292532A1 (https=)
BR (1) BR112012004237A8 (https=)
CA (1) CA2772068C (https=)
CR (1) CR20120120A (https=)
EA (1) EA201270325A1 (https=)
IL (1) IL218306B (https=)
IN (1) IN2012DN01911A (https=)
MX (1) MX2012002208A (https=)
SG (2) SG10201405069QA (https=)
WO (1) WO2011031503A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) * 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
JP6189962B2 (ja) 2012-10-09 2017-08-30 ザ プロクター アンド ギャンブル カンパニー 相乗作用する美容成分の組み合わせを特定する方法
US10302630B2 (en) 2012-10-09 2019-05-28 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
KR20170026624A (ko) * 2014-07-07 2017-03-08 알러간, 인코포레이티드 조직 샘플에서 절단된 snap25를 검출하는 방법
CN105044360A (zh) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010B (zh) * 2017-04-06 2018-12-11 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
ES3017696T3 (en) 2017-05-17 2025-05-13 Bpgbio Inc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US20230080670A1 (en) * 2019-04-05 2023-03-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating tumors using transcription inhibition and dna damage
JP2024509196A (ja) * 2021-03-05 2024-02-29 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 癌の治療のためのシャペロニン含有ｔｃｐ－１阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702148C (en) * 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
JP2006345701A (ja) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd タキサン類応答性の判別方法
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
KR101395370B1 (ko) * 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
JP2007536920A (ja) * 2004-05-14 2007-12-20 ラドウィッグ・インスティテュート・フォー・キャンサー・リサーチ イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1930445B1 (en) * 2005-09-02 2010-03-31 Toray Industries, Inc. Kit and method for detection of urothelial cancer
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8211634B2 (en) * 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8030013B2 (en) * 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
WO2009051277A1 (ja) * 2007-10-18 2009-04-23 Medical Proteoscope Co., Ltd. 手術後の予後を推定する方法及び診断キット

Similar Documents

Publication Publication Date Title
JP2013503175A5 (https=)
JP7654769B2 (ja) 外傷性脳傷害のバイオマーカー
KR102565758B1 (ko) 암 예후 예측방법 및 이의 조성물
ES2726650T5 (en) Methods of monitoring immunosuppressive therapies in a transplant recipient
AU2012321053A1 (en) Diagnostic assay for tissue transplantation status
Safarinejad et al. Glutathione S–transferase polymorphisms (GSTM1, GSTT1, GSTP1) and male factor infertility risk: a pooled analysis of studies
Gashaw et al. Gene signatures of testicular seminoma with emphasis on expression of ets variant gene 4
WO2016205572A1 (en) Method and kit for detecting hbv dna
JP2009509517A (ja) 肝細胞癌の分子マーカーおよびそれらの利用
US10233502B2 (en) Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer
Shaban et al. Distribution of glutathione S-transferase omega gene polymorphism with different stages of HBV infection including hepatocellular carcinoma in the Egyptian population
GB2486424A (en) Markers for plasma cell disorders
ES2336928T3 (es) Metodos de diagnostico y pronostico de esteatohepatitisno alcoholica (ehna).
CN110331207A (zh) 肺腺癌生物标志物及相关应用
Rim et al. Reduced lung fluid club cell secretory protein informs chronic lung allograft dysfunction risk
US20170356048A1 (en) Method for predicting receptivity to targeted anticancer drug
WO2016133212A1 (ja) 肝細胞癌に関する診断のために有用な背景肝因子及びその利用
AU2017270496B9 (en) Determination of genetic predisposition to aggressive prostate cancer
WO2019065609A1 (ja) Ｐｒｄｍ１４発現を確認する方法
CN107557470A (zh) 一种以人muc13作为肝细胞癌特异标志物的检测方法
Cheung et al. Preoperative plasma transcript AA454543 level is an independent prognostic factor for hepatocellular carcinoma after partial hepatectomy
WO2023007165A1 (en) Methods for assessing epigenetic age and cancer risk
WO2022144485A9 (es) Biomarcadores y método para predecir o pronosticar la respuesta al tratamiento con inhibidores de braf y de mek (brafi + meki)
CN117844924A (zh) 肾细胞癌的生物标志物bub1
Aal Human telomerase as a novel serum tumor marker for detection of hepatocellular carcinoma